Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation

European Journal of Cancer

Volumn 46, Issue 16, 2010, Pages 3016-3021

  De Jonge, Maja J A ^a   Slingerland, Marije ^b   Loos, Walter J ^a   Wiemer, Erik A C ^a   Burger, Herman ^a   Mathijssen, Ron H J ^a   Kroep, Judith R ^b   Den Hollander, Margret A G ^b   Van Der Biessen, Diane ^a   Lam, Mei Ho ^a   Verweij, Jaap ^a   Gelderblom, Hans ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cisplatin; LiPlaCis; Liposomal; Phase I; Solid tumour

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; CLEMASTINE; DEXAMETHASONE; LIPOSOMAL CISPLATIN; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ANEMIA; AREA UNDER THE CURVE; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ESOPHAGUS TUMOR; FATIGUE; FEMALE; HUMAN; HYPOPHARYNX CANCER; INFUSION REACTION; INJECTION SITE REACTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANCER; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE TUMOR; SOLID TUMOR; THROMBOCYTOPENIA; URINARY TRACT TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 78049280149     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.07.015     Document Type: Article

References (20)

1. F.E. de Jongh, R.N. van Veen, and S.J. Veltman Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients Br J Cancer 88 8 2003 1199 1206
2. R.S. Go, and A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 1 1999 409 422
3. A.S. Planting, M.E. van der Burg, M. de Boer-Dennert, G. Stoter, and J. Verweij Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours Br J Cancer 68 4 1993 789 792
4. W.C. Zamboni Concept and clinical evaluation of carrier-mediated anticancer agents Oncologist 13 3 2008 248 260
5. S.C. White, P. Lorigan, and G.P. Margison Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer Br J Cancer 95 7 2006 822 828
6. W.C. Zamboni, A.C. Gervais, and M.J. Egorin Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma Cancer Chemother Pharmacol 53 4 2004 329 336
7. J.P. Laye, and J.H. Gill Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discov Today 8 15 2003 710 716
8. T. Abe, K. Sakamoto, and H. Kamohara Group II phospholipase A2 is increased in peritoneal and pleural effusions in patients with various types of cancer Int J Cancer 74 3 1997 245 250
9. T.L. Andresen, S.S. Jensen, and K. Jorgensen Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release Prog Lipid Res 44 1 2005 68 97
10. S.S. Jensen, T.L. Andresen, and J. Davidsen Secretory phospholipase A2 as a tumor-specific trigger for targeted delivery of a novel class of liposomal prodrug anticancer etherlipids Mol Cancer Ther 3 11 2004 1451 1458
11. .
12. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment of solid tumours J Natl Cancer Inst 92 2000 205 216 (Pubitemid 30099779)
13. M.J. de Jonge, W.J. Loos, and H. Gelderblom Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects J Clin Oncol 18 10 2000 2104 2115
14. H.C. Kwaan, and L.I. Gordon Thrombotic microangiopathy in the cancer patient Acta Haematol 106 1-2 2001 52 56
15. G.P. Stathopoulos, T. Boulikas, and M. Vougiouka Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study Oncol Rep 13 4 2005 589 595
16. M.I. Koukourakis, A. Giatromanolaki, and M. Pitiakoudis Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study Int J Radiat Oncol Biol Phys 2010 [Epub ahead of print]
17. D.S. Alberts, and D.J. Garcia Safety aspects of pegylated liposomal doxorubicin in patients with cancer Drugs 54 Suppl. 4 1997 30 45
18. S. Urien, E. Brain, and R. Bugat Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients Cancer Chemother Pharmacol 55 1 2005 55 60
19. J.M. Meerum Terwogt, G. Groenewegen, and D. Pluim Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin Cancer Chemother Pharmacol 49 3 2002 201 210
20. P.A. Reece, I. Stafford, J. Russell, and P.G. Gill Reduced ability to clear ultrafilterable platinum with repeated courses of cisplatin J Clin Oncol 4 9 1986 1392 1398